The pathogenesis of the polycystic ovary syndrome: A hypothesis

Endocrine Practice

Volumn 8, Issue 2, 2002, Pages 127-132

  Gabrilove, J Lester ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3(OR 17)BETA HYDROXYSTEROID DEHYDROGENASE; ANDROGEN; ANTIANDROGEN; ANTIESTROGEN; AROMATASE; CLOMIFENE; DEXAMETHASONE; DIANE; ESTROGEN; FLUTAMIDE; FOLLITROPIN; GONADORELIN AGONIST; GONADOTROPIN; HYDROXYPROGESTERONE; LUTEINIZING HORMONE; METFORMIN; STEROID 11BETA MONOOXYGENASE; STEROID 21 MONOOXYGENASE; TESTOSTERONE; TROGLITAZONE;

ADOLESCENT; ADULT; ARTICLE; CHILD; CONTROLLED STUDY; DISEASE ASSOCIATION; DRUG EFFICACY; DRUG SENSITIZATION; ENZYME DEFICIENCY; ESTROGEN SYNTHESIS; FEMALE; GENE MUTATION; GLUCOSE TOLERANCE; HORMONE ACTION; HUMAN; INSULIN RESISTANCE; MALE; MOUSE; NONHUMAN; OBESITY; OVARY POLYCYSTIC DISEASE; PATHOGENESIS; VIRILIZATION;

EID: 0036130093     PISSN: 1530891X     EISSN: None     Source Type: Journal    
DOI: 10.4158/ep.8.2.127     Document Type: Article

References (59)

1. Amenorrhea associated with bilateral polycystic ovaries
2. Defective biosynthesis of ovarian steroids in the Stein-Leventhal syndrome
3. Diseases associated with some enzymic defects in the gonads and adrenal cortex
4. Estrogen: Consequences and implications of human mutations in synthesis and action
5. Clinical review 78: Aromatase deficiency in women and men: Would you have predicted the phenotypes?
6. Polycystic ovary syndrome as a form of functional ovarian hyperandrogenism due to dysregulation of androgen secretion
7. Thirty-seven candidate genes for polycystic ovary syndrome: Strongest evidence for linkage is with follistatin
8. The pathogenesis of gynecomastia
9. Feminizing adrenocortical tumors in the male-a review of 52 cases
10. Feminizing interstitial cell tumor of the testis: Personal observations and a review of the literature
11. Feminizing and non-feminizing Sertoli cell tumors
12. Biosynthesis of testosterone and oestrogen in vitro by the testicular tissue from patients with Klinefelter's syndrome
13. Virilizing adrenal adenoma with studies on the steroid content of the adrenal venous effluent and a review of the literature
14. Formation of androgens by human arrhenoblastoma tissue (in vitro)
15. Congenital adrenal hyperplasia due to 21-hydroxylase deficiency
16. Gynecomastia and bilateral testicular masses secondary to congenital adrenal hyperplasia (21-hydroxylase deficiency)
17. Influence of different genotypes on 17-hydroxyprogesterone levels in patients with nonclassical congenital adrenal hyperplasia due to 21-hydroxylase deficiency
18. A new cause of female pseudohermaphroditism: Placental aromatase deficiency
19. A syndrome of female pseudohermaphrodism, hypergonadotropic hypogonadism, and multicystic ovaries associated with missense mutations in the gene encoding aromatase (P450arom)
20. Aromatase deficiency in male and female siblings caused by a novel mutation and the physiological role of estrogens
21. Effect of testosterone and estradiol in a man with aromatase deficiency
22. Aromatase deficiency in a female who is a compound heterozygote for two new point mutations in the P450arom gene: Impact of estrogens on hypergonadotropic hypogonadism, multicystic ovaries, and bone densitometry in childhood
23. Aromatase deficiency caused by a novel P450arom gene mutation: Impact of absent estrogen production on serum gonadotropin concentration in a boy
24. Female pseudohermaphroditism (FPH) resulting from aromatase (P450arom) deficiency associated with a novel mutation (R457X) in the CYP19 gene
25. Female pseudohermaphroditism associated with a novel homozygous G-to-A (V370-to-M) substitution in the P-450 aromatase gene
26. Estrogen resistance caused by a mutation in the estrogen-receptor gene in a man
27. Effect of estrogen deprivation on the reproductive physiology of male and female primates
28. Characterization of mice deficient in aromatase (ArKo) because of targeted disruption of the cyp19 gene
29. Estrogen receptor gene disruption: Molecular characterization and experimental and clinical phenotypes
30. Hormonal effects of flutamide in young women with polycystic ovary syndrome
31. Efficacy of the combination ethinyl oestradiol and cyproterone acetate on endocrine, clinical and ultrasonographic profile in polycystic ovarian syndrome
32. Histopathological effects of exogenously administered testosterone in 19 female to male transsexuals
33. The effects of long term testosterone administration on pulsatile luteinizing hormone secretion and on ovarian histology in eugonadal female to male transsexual subjects
34. A higher rate of hyperandrogenic disorders in female-to-male transsexuals
35. Pituitary-ovarian responses to nafarelin testing in the polycystic ovary syndrome
36. Evidence for a primary abnormality of thecal cell steroidogenesis in the polycystic ovary syndrome
37. Studies on the nature of 17-hydroxyprogesterone hyperresponsiveness to gonadotropin-releasing hormone agonist challenge in functional ovarian hyperandrogenism
38. Ovarian hyperandrogenism as a result of congenital adrenal virilizing disorders: Evidence for perinatal masculinization of neuroendocrine function in women
39. Polycystic ovaries associated with congenital adrenal hyperplasia
40. Adrenocorticoid IIB-hydroxylase deficiency and virilism first manifest in the adult woman
41. Clinical aspects of sexual abnormalities in man
42. The prevalence of polycystic ovaries in women with type 2 diabetes mellitus
43. Prevalence of a positive family history of type 2 diabetes in women with polycystic ovarian disease
44. Insulin stimulates testosterone biosynthesis by human thecal cells from women with polycystic ovary syndrome by activating its own receptor and using inositolglycan mediators as the signal transduction system
45. Clinical implications of hyperinsulinaemia in women
46. Clinical presentation of PCOS following development of an insulinoma: Case report
47. Insulinoma presenting with hyperandrogenism
48. Normal ovulatory women with polycystic ovaries have hyperandrogenic pituitary-ovarian responses to gonadotropin-releasing hormone-agonist testing
49. Androgen activity as a risk factor for impaired glucose tolerance in postmenopausal women
50. Effects of two antiandrogen treatments on hirsutism and insulin sensitivity in women with polycystic ovary syndrome
51. Do estrogens reduce glycemic levels?
52. Effect of postmenopausal hormone therapy on glucose and insulin concentrations
53. Troglitazone improves defects in insulin action, insulin secretion, ovarian steroidogenesis, and fibrinolysis in women with polycystic ovary syndrome
54. Metformin effects on clinical features, endocrine and metabolic profiles, and insulin sensitivity in polycystic ovary syndrome: A randomized, double-blind, placebo-controlled 6-month trial, followed by open, evaluation
55. Metformin therapy decreases hyperandrogenism and hyperinsulinemia in women with polycystic ovary syndrome
56. Ovarian follicle atresia: A hormonally controlled apoptotic process
57. Functional studies of aromatase activity in human granulosa cells from normal and polycystic ovaries
58. Manipulation of human ovarian function: Physiological concepts and clinical consequences